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A multiresistant Klebsiella pneumoniae isolate was taken from the blood of a 75-year-old patient with
nosocomial pneumonia who developed septic shock and failed therapy with imipenem. The isolate presented an
MIC of imipenem of 128 g/ml, and the production of a metallo--lactamase was confirmed by phenotypic and
genotypic techniques. We here report, for the first time, the detection of a metalloenzyme (IMP-1)-producing
K. pneumoniae clinical strain in Latin America. The gene responsible for this phenotype was found to be
blaIMP-1, carried in a class 1 integron.
CASE REPORT
In April 2003, a 75-year-old man with a previous history of
diabetes and hypertension was admitted with a hemorrhagic
cerebral vascular accident to the Hospital Universita´rio da
Universidade de Sa˜o Paulo, a secondary university hospital. He
was put under mechanical ventilation and was transferred to a
tertiary care hospital, the Hospital das Clı´nicas da Univer-
sidade de Sa˜o Paulo, for specialized medical care. Four days
after his admission, he developed pneumonia and was treated
with cefepime (2 g/day). The antibiotic doses were adjusted
based on the patient’s creatinine clearance, which was esti-
mated to be of 30 ml/min. Two days later, he was readmitted to
the Hospital Universita´rio, where therapy was changed to
ceftazidime at 2 g/day and clindamycin at 2.4 g/day. In our
hospital ceftazidime and clindamycin are the antibiotics indi-
cated for aspirative pneumonia. Cefepime was not available.
Taking into account that there was no clinical improvement
and that a bronchoalveolar-lavage culture yielded Acineto-
bacter baumannii resistant to cephalosporins and ciprofloxacin,
the treatment was changed to meropenem (2 g/day) (due to an
adjustment for renal failure), which was taken for 14 days.
Persistence of fever and a positive urine culture for Candida
tropicalis led to the administration of fluconazole (400 mg/day).
The patient then presented skin infection secondary to phle-
bitis and was treated with vancomycin at 500 mg/day for 7 days,
once Staphylococcus epidermidis was isolated in two blood sam-
ples.
After a week without antibiotics fever and leucocytosis re-
turned and treatment with vancomycin and imipenem (IMP)
was empirically initiated, with respective doses of 500 mg/day
and 250 mg times a day. Stenotrophomonas maltophilia, Kleb-
siella pneumoniae, and Staphylococcus aureus isolates were re-
covered from a tracheal aspirate culture and were managed as
colonizers. The S. maltophilia strain was resistant to multiple
antibiotics, whereas the K. pneumoniae strain was susceptible
to carbapenems and cephalosporins. The S. aureus strain was
also multiresistant.
Because the patient presented sepsis without a focus and
had received broad-spectrum antibiotics a few days before, the
multiresistant colonizers could be associated to sepsis and were
treated empirically.
The patient showed clinical improvement, and the treatment
was completed after 14 days. On the same day, fever returned,
and 3 days later the patient presented a positive blood culture
for a multidrug-resistant K. pneumoniae strain (strain KPBr1).
Because the only new sign of infection was fever, which was
under investigation, the patient was not treated. Unfortu-
nately, the patient deceased within a few hours after a positive
blood culture result due to septic shock after being hospital-
ized for 53 days was reported.
Initially, the identification and the antimicrobial susceptibil-
ity profile of strain KPBr1 were evaluated using a Vitek system
(BioMe´rieux, Hazlewood, Mo.). The MICs were subsequently
determined using both an agar dilution method and an Etest
according to NCCLS recommendations (11) and the manufac-
turer’s instructions (AB Biodisk, Solna, Sweden). Hydrolysis of
IMP was evaluated with bioassays (7) using either S. aureus
ATCC 25923 or Micrococcus luteus ATCC 9341; these bioas-
says involved satellite growth of these strains around the K.
pneumoniae strain growing on Mueller-Hinton agar plates con-
taining 108 CFU of ATCC strains/ml and IMP at a concentra-
tion of 0.06 or 0.12 g/ml. The isolate was screened for me-
tallo--lactamase (MBL) production by a double disk-synergy
test using ceftazidime and IMP as substrates and EDTA and
thiol compounds (2-mercaptopropionic acid and 2-mercapto-
acetic acid) as -lactamase inhibitors (1). The MIC of IMP
with and without EDTA was then measured by dilution in agar
(11). Isoelectric focusing was performed using crude -lacta-
mase extracts in polyacrylamide gels containing ampholines
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with a pH range of 3.5 to 9.5 as previously described (5), and
DNA amplification by PCR was carried out using primers
specific to the blaIMP-1 gene and blaCTX-M genes (3, 13). Both
strands of the amplification products of the blaIMP gene were
sequenced by the standard Sanger dideoxynucleotide method
(17).
The resistant organism was confirmed to be K. pneumoniae
by standard biochemical tests. Imipenemase activity was inhib-
ited by thiol compounds or EDTA but not by clavulanic acid or
tazobactam (Fig. 1). The KPBr1 strain presented an MIC of
IMP of 128 g/ml in the absence of EDTA and an MIC of IMP
of 1 g/ml in the presence of EDTA (Table 1), thereby sug-
gesting the production of an MBL. The pI of this enzyme was
estimated to be 9.5 (13). DNA amplification by PCR yielded
a fragment of approximately 600 bp, and nucleotide sequenc-
ing showed that the blaIMP gene of strain KPBr1 was identical
to the blaIMP-1 gene first described for Serratia marcescens (13)
(GenBank accession no. S71932).
Isoelectric focusing analysis showed that this strain (KPBr1)
produced another -lactamase with a pI of 7.9, which corre-
sponds to a cefotaximase (most likely CTX-M-2), since this
strain also possessed an extended-spectrum -lactamase
(ESBL) phenotype (Table 1) and genotype (DNA amplifica-
tions by PCR using primers specific to the blaCTX-M gene
yielded a fragment of approximately 550 bp).
The KpBr1 isolate was tested for the presence of class 1
integrons by PCR using primers for the 5 and 3 conserved
sequences of class 1 integrons. Moreover, the presence of
blaIMP-1 and blaCTX-M genes in these integrons was tested by
PCR by using (i) a forward primer for the conserved sequence
of class 1 integrons with a reverse primer for either blaIMP-1 or
blaCTX-M genes and (ii) a forward primer for either blaIMP-1
or blaCTX-M genes with a reverse primer for the conserved
sequence of class 1 integrons (GenBank accession no.
AF133699).
As observed by electrophoresis, the KpBr1 strain contains
plasmids. Despite repeated attempts, however, experimental
transformation of plasmid DNA into Escherichia coli DH5
was unsuccessful even by electroporation. Conjugation exper-
iments between the clinical isolate KpBr1 and E. coli K12 did
not yield any transconjugants. Although the blaIMP-1 gene was
found to be on a mobile element, a class 1 integron, in strain
KpBr1, it seems that this gene is carried chromosomally.
Production of the IMP enzyme caused reduced susceptibility
to almost all -lactam antibiotics, including penicillins, cepha-
losporins, and carbapenems. The reduced susceptibility to az-
treonam (AZT) observed was most likely due to CTX-M pro-
duction. A ghost zone between the amoxicillin-clavulanic acid
disk and the AZT disk was observed with a Kirby-Bauer disk
diffusion test (Fig. 1). The ESBL phenotype was thus verified
FIG. 1. Appearance of a zone of growth inhibition in CTX-M- and IMP-producing K. pneumoniae strain KpBr-1. An assay using AZT (ATM),
amoxicillin-clavulanic acid (AMC), and ceftazidime (CAZ) (top left panel) and an assay using AZT (ATM) and ticarcillin-clavulanic acid (TIM)
for ESBL screening (bottom left panel) for ESBL screening are shown. (Right panel) Results of an assay for MBL screening using CAZ,
2-mercaptoacetic acid (2-MAA), 2-mercaptopropionic acid (2-MPA), EDTA, and IMP. Marked growth inhibition of KpBr-1 was observed for both
-lactamases.
TABLE 1. Antimicrobial susceptibility profile of the K. pneumoniae
strain KPBr-1 carrying the blaIMP-1 and blaCTX-M genes
Antimicrobial agent
MIC (g/ml)
Vitek system Etest Agar dilutionmethod
Piperacillin 64
Piperacillin-tazobactam 64
AZT 16, ESBLc 12
Cefoxitin 16 256 512
Ceftriaxone 32, ESBL 256 512
Cefotaxime 32, ESBL 512
Cefotaxime-clavulanic acid 512a
Cefotaxime-EDTA 256b
Ceftazidime 16 256 256
Ceftazidime-clavulanic acid 32–4.0 256a
Ceftazidime-EDTA 2b
Cefpodoxime 1
Cefepime 16 256
Ciprofloxacin 2 32
IMP 8 32 128
IMP-clavulanic acid 128a
IMP-EDTA 1b
a Clavulanic acid was tested at a fixed concentration of 4 g/ml.
b EDTA was tested at a fixed concentration of 320 g/ml.
c ESBL, carrying an ESBL phenotype.
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by clavulanic acid inhibition, in the presence of AZT, which is
not a substrate for MBL enzymes. The resistance to AZT in
KpBr1 was encoded by an additional CTX-M-type gene, as
determined by PCR.
The production of these two enzymes by the strain contrib-
uted to treatment failure and death of the patient.
Discussion. As opportunistic pathogens, Klebsiella spp. pri-
marily thrive in immunocompromised individuals who are hos-
pitalized and suffer from severe underlying diseases such as
diabetes mellitus or chronic pulmonary obstruction (14). Nos-
ocomial Klebsiella infections are caused mainly by K. pneu-
moniae, the medically most important species of the genus.
The principal reservoirs for transmission of Klebsiella are the
gastrointestinal tract and the hands of hospital personnel (14).
Because of their ability to spread rapidly in the hospital envi-
ronment, these bacteria tend to cause nosocomial outbreaks.
The main problem concerning these infections is that ESBL-
producing strains among clinical Klebsiella isolates appear to
be common in Latin American countries. For example, in a
worldwide study including isolates from Europe, the Americas,
and the Western Pacific region (21) the SENTRY Antimicro-
bial Surveillance Program noted the highest prevalence
(45.4%) of ESBL production by K. pneumoniae in South
America. In Brazil, CTX-M is the most prevalent class of
ESBL found and is widely disseminated (2, 3, 21). The inten-
sive use of broad-spectrum cephalosporins such as cefotaxime
could account for the emergence and spread of the CTX-M
enzymes whose genes are carried in plasmids among nosoco-
mial pathogens in Brazilian hospitals (3).
Carbapenems, such as IMP and meropenem, are used ever
more frequently for the treatment of multiresistant gram-neg-
ative nosocomial pathogens, especially strains that produce
ESBLs, once they are stable with respect to these enzymes
(16). Because of the high prevalence of ESBL production in
nosocomial strains, selective pressure inflicted by the frequent
use of carbapenems has led to high levels of resistance to these
drugs among strains of gram-negative bacilli (9, 12).
Resistance to carbapenems is still rare in Enterobacteriaceae
strains, where it is generally due to an AmpC enzyme hyper-
production, coupled with alteration in outer membrane per-
meability (9, 12). On the other hand, it has been observed
more frequently among nonfermentative gram-negative bacilli.
In Acinetobacter strains, it is mostly due to class D serine
-lactamases in Europe and MBLs in Asia (12). Currently
there have been a growing number of reports indicating an
increase in the prevalence of carbapenemases (4, 8, 13, 19).
Basically, two molecular classes of carbapenem-hydrolyzing
enzymes, classes A (Bush group 2f) and B (Bush group 3), have
been described. Class B enzymes or MBLs are clinically rele-
vant, since they are able to degrade virtually all -lactams
except monobactams. In contrast to ESBLs, MBLs are not
inhibited by -lactamase inhibitors such as clavulanic acid and
tazobactam; however, they are inhibited by EDTA and/or thiol
compounds (1, 15). Three different types of mobile MBLs have
been described in the literature: IMP, VIM, and SPM. IMP
and VIM enzymes have been found in various gram-negative
clinical isolates, mostly in the Far East and the Mediterranean
region (12, 13, 19).
In Latin America, recent studies have characterized the ap-
pearance of metalloenzymes such as IMP and SPM (a novel
MBL) in Brazilian clinical isolates of A. baumannii and
Pseudomonas aeruginosa, respectively (4, 5, 20). Moreover,
VIM-type MBLs from Pseudomonas sp. isolates from Chile
and Venezuela have been reported by the SENTRY Antimi-
crobial Surveillance Program (R. E. Mendes, M. Castanheira,
P. Garcia, M. Guzman, M. A. Toleman, T. R. Walsh, and R. N.
Jones, Letter, Antimicrob. Agents Chemother. 48:1433–1434,
2004).
The detection of MBLs in K. pneumoniae has occurred spo-
radically. Among these MBLs, IMP-1 and IMP-8 have been
described in studies of K. pneumoniae, the former in Japan (18)
and Singapore (T. H. Koh, G. S. Babini, N. Woodford, L. H.
Sng, L. M. C. Hall, and D. M. Livermore, Letter, Lancet
353:2162, 1999) and the latter in Taiwan (23). VIM-1 and
VIM-4 have recently been described in Greece and Italy (6,
10). Gram-negative bacilli producing both IMP-like and
CTX-M enzymes have been recently reported (22). From this
study, we report the presence of both enzymes in the KpBr1
strain, coded by blaIMP-1 and blaCTX-M; the former is found to
be in a class 1 integron.
To our knowledge, this is the first report of a clinical isolate
of K. pneumoniae producing an MBL in Latin America. The
occurrence of carbapenem-resistant K. pneumoniae in Brazil is
alarming, since it jeopardizes treatment with carbapenems.
This class of antimicrobial agents is the main therapeutic op-
tion for treating infections caused by both ESBL-producing
strains and nonfermentative gram-negative bacilli, which are
highly prevalent in most Brazilian hospitals. Microorganisms
are notorious for their ability to spread among patients and to
act as harborers of resistance plasmids.
CTX-M-encoding genes have primarily been found on plas-
mids; however, secondary chromosomal insertions of blaCTX-M
genes have also been observed in clinical E. coli strain HK56 in
Japan (2). These data suggest mobility of the blaCTX-M and
blaIMP-1 genes, which allows for their transference between
plasmids and from plasmids to chromosomes (2). Since inte-
grons are carried on plasmids and transposons, a strong anti-
biotic selective pressure can potentially result in the mobiliza-
tion and dissemination of antibiotic resistance genes.
Certainly, the mobility of gene cassettes (blaCTX or blaIMP)
combined with the flexibility of class 1 integrons suggests that
resistance to cephalosporins and carbapenems will continue to
increase and would confer an enormous potential for the dis-
semination of these genes into other nosocomial pathogens.
Mobile -lactamases will pose a serious threat to broad-spec-
trum beta-lactam therapies within Brazilian hospitals.
Nosocomial Infection Control Committees in Brazilian hos-
pitals should thus be on the lookout for potential outbreaks
involving this kind of strain.
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